端粒酶逆转录酶在泌尿生殖系肿瘤中的研究进展  

Research progress of telomerase reverse transcriptase in urogenital carcinoma

作　　者：王倚天[1] 张蒙[1] 王波[1] 蔡志明[1] 吴松[1,2] 

机构地区：[1]安徽医科大学深圳市第二人民医院临床医学院,深圳518000 [2]中山大学中山医学院,广州510000

出　　处：《生命科学》2014年第8期804-808,共5页Chinese Bulletin of Life Sciences

基　　金：国家重点基础研究发展计划("973"项目)(2014CB745200);国家自然科学基金项目(81301740);深圳市基础研究项目(JCYJ20130401114928183;JCYJ20130401114715714)

摘　　要：端粒酶和端粒长短的变化与人类肿瘤的发生发展息息相关。其中,发生在端粒酶逆转录酶(telomerase reverse transcriptase,TERT)启动子区域的体细胞突变对泌尿生殖系统肿瘤的发生具有重大影响。此外,TERT的表达已被证明与肿瘤患者预后不佳相关。旨在总结TERT在泌尿生殖系肿瘤发生发展中可能的作用以及揭示TERT作为判断疾病预后的生物标志物和肿瘤靶向治疗新靶点的巨大潜能。Telomerase and the control of telomere length are closely related to the development of human cancer. Mutations in the promoter region of telomerase reverse transcriptase （TERT） will have an enormous impact on the tumourigenesis process of urogenital tumour. In addition, the expression of TERT has also been proved to have correlations with poor prognosis. This article summarizes the current potential roles of TERT in the tumorigenesis and development of urogenital carcinoma, suggests that TERT holds promise as a biomarker for the evaluation of prognosis, and has great potential as the basis for targeted therapies.

关 键 词：端粒酶逆转录酶 泌尿生殖肿瘤 靶向治疗 

分 类 号：Q55[生物学—生物化学] R737.1[医药卫生—肿瘤]